Radotinib

CAS No. 926037-48-1

Radotinib( IY-5511 )

Catalog No. M16635 CAS No. 926037-48-1

Radotinib, and sometimes referred to by its investigational name IY5511.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 35 In Stock
10MG 53 In Stock
25MG 110 In Stock
50MG 178 In Stock
100MG 335 In Stock
500MG 782 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Radotinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Radotinib, and sometimes referred to by its investigational name IY5511.
  • Description
    Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    IY-5511
  • Pathway
    Tyrosine Kinase
  • Target
    Bcr-Abl
  • Recptor
    Bcr-Abl1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    926037-48-1
  • Formula Weight
    530.5
  • Molecular Formula
    C27H21F3N8O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    CC1=CN(C=N1)C1=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=NC=CN=C3)=C(C)C=C2)=CC(=C1)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Heo SK, et al. PLoS One. 2015 Jun 12;10(6):e0129853.
molnova catalog
related products
  • Precyasterone

    Precyasterone is a natural product isolated from the dried roots of?Cyathula capitata.

  • Dasatinib monohydrat...

    Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML).

  • TIC10 isomer

    TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.